Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical capsaicin Clear all
Completed Phase 3 Interventional Results available

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

NCT04967664
View directory record Official record
Conditions
Post Surgical Neuropathic Pain
Interventions
Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system
Drug
Lead sponsor
Averitas Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • Vista, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Topical Capsaicin for Cyclical Vomiting

NCT03223350
View directory record Official record
Conditions
Cyclical Vomiting
Interventions
Capsaicin 0.1% Cream, Placebos
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Phase 2 Interventional

Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)

NCT00916942
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
capsaicin 8%, Lidocaine (2.5%)/Prilocaine (2.5%) Cream
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
Naples, Florida • St. Petersburg, Florida • Marietta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2009 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects

NCT00655811
View directory record Official record
Conditions
Healthy
Interventions
Capsaicin, Placebo moisturizing cream
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 21, 2026, 10:45 PM EDT
Not yet recruiting Phase 4 Interventional

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

NCT07795593
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions
Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Early Phase 1 Interventional Results available

Biomarker Study in Participants With Migraine

NCT02766517
View directory record Official record
Conditions
Migraine Disorders
Interventions
Capsaicin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Phoenix, Arizona • Encino, California • Glendale, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 21, 2026, 10:45 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy of Topical Capsaicin Cream for Stable Angina

NCT01231750
View directory record Official record
Conditions
Stable Angina
Interventions
Capsaicin, Placebo cream
Drug · Other
Lead sponsor
Neal Weintraub
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 21, 2026, 10:45 PM EDT
Recruiting Not applicable Interventional

Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response

NCT04142177
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Pain EASE, Tailored exercise, Continued Care and Active Monitoring, Cognitive Behavioral Therapy (CBT), Spinal Manipulation Therapy (SMT), Yoga
Other · Procedure · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Thermosensitivity of a Topical Palmitated Formulation of Capsaicin

NCT05649228
View directory record Official record
Conditions
Pain Management
Interventions
Capsaicin 0.1% Cream, Capsaicin Palmitate 0.25% Cream, Placebo Cream
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
35 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population

NCT05093478
View directory record Official record
Conditions
Non-allergic Rhinitis
Interventions
Intranasal capsaicin, topical lidocaine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 21, 2026, 10:45 PM EDT
Enrolling by invitation No phase listed Observational

Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy

NCT06540456
View directory record Official record
Conditions
Lower Back Pain, Lumbosacral Radiculopathy
Interventions
Qutenza® 8% Capsaicin Topical System
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Summerville, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis

NCT03576508
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CNTX-4975-05, Qutenza, Lidocaine (without epinephrine)
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
50 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Phase 4 Interventional

Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome

NCT04283292
View directory record Official record
Conditions
Cannabinoid Hyperemesis Syndrome
Interventions
Capsaicin, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 21, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Spinal Ketorolac After Acute Opioid Exposure

NCT00693160
View directory record Official record
Conditions
Healthy
Interventions
ketorolac, placebo, remifentanil, Capsaicin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 21, 2026, 10:45 PM EDT
Recruiting Early Phase 1 Interventional

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

NCT06744816
View directory record Official record
Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
Qutenza Patch
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 21, 2026, 10:45 PM EDT
Withdrawn Phase 2 Interventional

Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain

NCT00795106
View directory record Official record
Conditions
Myofascial Pain Syndrome
Interventions
Capsaicin, Placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 21, 2026, 10:45 PM EDT
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

Pain Biomarker Study

NCT03511846
View directory record Official record
Conditions
Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Hemicrania Continua, Paroxysmal Hemicrania, SUNCT, Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and Tearing
Interventions
Oral capsaicin, Topical capsaicin, Intranasal capsaicin, Cold Water Irrigation, Medical Air, Low Flow Oxygen, High Flow Oxygen
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Tolerability and Effects on Epidermal Nerve Fiber Density of Multiple Low-Concentrations of NGX-1998 in Healthy Volunteers

NCT00912262
View directory record Official record
Conditions
Pain
Interventions
Capsaicin Topical Liquid
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 21, 2026, 10:45 PM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Transient Receptor Potential Channels

NCT06444594
View directory record Official record
Conditions
Aging
Interventions
TRPM8 Agonist, TRPV1 Agonist, TRPV4 Agonist, TRPM8, TRPV4, TRPV1 Agonists, Vehicle gel
Drug · Other
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy

NCT05098067
View directory record Official record
Conditions
Hyperemesis Gravidarum, Nausea Gravidarum, Vomiting of Pregnancy
Interventions
Capsaicin Topical Cream, Metoclopramide, Ondansetron, Lactated Ringers, Intravenous
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches

NCT05106400
View directory record Official record
Conditions
Healthy
Interventions
ZTlido (Lidocaine Topical System) 1.8%, Salonpas (Lidocaine Patch 4%), Aspercreme (Lidocaine Patch 4%), IcyHot (Lidocaine 4% + Menthol 1% Patch)
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Sickle Cell Pain: Intervention With Capsaicin Exposure

NCT03899246
View directory record Official record
Conditions
Neuropathic Pain, Sickle Cell Disease
Interventions
Eight Percent Topical Capsaicin
Drug
Lead sponsor
Children's Hospital of Michigan
Other
Eligibility
14 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 21, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Results available

FS-67 in the Treatment of Pediatric Patients With Ankle Sprain

NCT01037816
View directory record Official record
Conditions
Ankle Sprain
Interventions
FS-67 Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 21, 2026, 10:45 PM EDT
Active, not recruiting No phase listed Observational

Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

NCT06495424
View directory record Official record
Conditions
Peripheral Diabetic Neuropathy, Painful Diabetic Neuropathy
Interventions
Capsaicin 8%
Drug
Lead sponsor
Averitas Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Wilmington, Delaware • Gainesville, Georgia • Jasper, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 21, 2026, 10:45 PM EDT